Current study on diagnosis and treatment of Alzheimer?s disease by targeting amyloid ?-protein

Alzheimer's disease (AD), also known as senile dementia, is a degenerative disease of the central nervous system and is characterized by insidious onset and a chronic progressive course. It is the most common type of senile dementia. Studies have proved that the deposition of amyloid beta (A beta) in the brain is one of the initiating factors correlated to the pathology of AD, and it acts as one of the critical factors leading to the onset of AD. A large number of long-term studies have shown that A beta may be a therapeutic target for a breakthrough in the treatment of AD. This review elucidates the important role of A beta in the development of AD, current research on the role of A beta in AD pathogenesis, and treatment of AD by targeting A beta.